This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.
Signed and dated informed consent form.
Male or female, > 18 years old.
Minimum body weight of 50 kilograms (kg).
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30 days prior to study Day 1.
Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.
Active autoimmune disease requiring immunosuppressive therapy.
Infection requiring systemic treatment within 30 days prior to study Day 1.
Kiromic BioPharma Inc.
Lead sponsor
Stiris Research Inc
Collaborator